System Formulary Update
Triamcinolone Acetonide Suprachoroidal (Xipere)
Situation
The formulary addition proposal for triamcinolone acetonide injectable suspension for suprachoroidal use (Xipere) was approved at the May 2022 System P&T Committee meeting.
Background
The following medications were reviewed via a medication use evaluation: triamcinolone acetonide suprachoroidal (Xipere)
Assessment/Recommendation
Change effective: Tuesday, July 19th
System P&T voted to include the following products on the UNC Health Medication Formulary: